{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:20:29Z","timestamp":1790644829043,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and\/or Proximal Popliteal Artery) was designed to evaluate the patency of the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, compared with BMSs for the treatment of femoropopliteal artery lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>EMINENT is a prospective, randomized, controlled, multicenter European study with blinded participants and outcome assessment. Patients with symptomatic peripheral artery disease (Rutherford category 2, 3, or 4) of the native superficial femoral artery or proximal popliteal artery with stenosis \u226570%, vessel diameter of 4 to 6 mm, and total lesion length of 30 to 210 mm were randomly assigned 2:1 to treatment with DES or BMS. The primary effectiveness outcome was primary patency at 12 months, defined as independent core laboratory\u2013assessed duplex ultrasound peak systolic velocity ratio \u22642.4 in the absence of clinically driven target lesion revascularization or surgical bypass of the target lesion. Primary sustained clinical improvement was a secondary outcome defined as a decrease in Rutherford classification of \u22651 categories compared with baseline without a repeat target lesion revascularization. Health-related quality of life and walking function were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 775 patients were randomly assigned to treatment with DES (n=508) or commercially available BMSs (n=267). Baseline clinical, demographic, and lesion characteristics were similar between the study groups. Mean lesion length was 75.6\u00b150.3 and 72.2\u00b147.0 mm in the DES and BMS groups, respectively. The 12-month incidence of primary patency for DES treatment (83.2% [337 of 405]) was significantly greater than for BMS (74.3% [165 of 222];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01). Incidence of primary sustained clinical improvement was greater among patients treated with the DES than among those who received a BMS (83.0% versus 76.6%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.045). The health-related quality of life dimensions of mobility and pain\/discomfort improved for the majority of patients in both groups (for 66.4% and 53.6% of DES-treated and for 64.2% and 58.1% of BMS-treated patients, respectively) but did not differ significantly. At 12 months, no statistical difference was observed in all-cause mortality between patients treated with the DES or BMS (2.7% [13 of 474] versus 1.1% [3 of 263]; relative risk, 2.4 [95% CI, 0.69\u20138.36];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>By demonstrating superior 1-year primary patency, the results of the EMINENT randomized study support the benefit of using a polymer-based paclitaxel-eluting stent as a first-line stent-based intervention for patients with symptomatic peripheral artery disease attributable to femoropopliteal lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>URL: https:\/\/www.clinicaltrials.gov; Unique identifier: NCT02921230.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.122.059606","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T14:00:31Z","timestamp":1669039231000},"page":"1564-1576","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":109,"title":["Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial"],"prefix":"10.1161","volume":"146","clinical-trial-number":[{"clinical-trial-number":"nct02921230","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9246-1503","authenticated-orcid":false,"given":"Yann","family":"Gou\u00ebffic","sequence":"first","affiliation":[{"name":"Groupe Hospitalier Paris St. Joseph, Department of Vascular and Endovascular Surgery, Paris, France (Y.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Torsello","sequence":"additional","affiliation":[{"name":"St. Franziskus-Hospital M\u00fcnster, M\u00fcnster, Germany (G.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeller","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany (T.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-7127","authenticated-orcid":false,"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, Italy (G.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vermassen","sequence":"additional","affiliation":[{"name":"Gent University Hospital, Belgium (F.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Armin","family":"Hausegger","sequence":"additional","affiliation":[{"name":"Klinikum Klagenfurt am W\u00f6rthersee, Austria (K.A.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tepe","sequence":"additional","affiliation":[{"name":"Klinikum Rosenheim, Germany (G.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thieme","sequence":"additional","affiliation":[{"name":"REGIOMED Vascular Center Sonneberg, Germany (M.T.)."},{"name":"Jena University Hospital, Clinic for Internal Medicine I, Germany (M.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gschwandtner","sequence":"additional","affiliation":[{"name":"Medizinische Universit\u00e4t Wien, Austria (M.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-7159","authenticated-orcid":false,"given":"Andrea","family":"Kahlberg","sequence":"additional","affiliation":[{"name":"Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy (A.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schindewolf","sequence":"additional","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern (M. Schindewolf)."},{"name":"University Hospital, University of Bern, Switzerland (M. Schindewolf)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sapoval","sequence":"additional","affiliation":[{"name":"H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France (M. Sapoval)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Diaz-Cartelle","sequence":"additional","affiliation":[{"name":"Boston Scientific Corp, Marlborough, MA (J.D.-C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9775-9210","authenticated-orcid":false,"given":"Konstantinos","family":"Stavroulakis","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilian University, Munich, Germany (K.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EMINENT Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"R1-20250409","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries.","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"R2-20250409","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jacc.2018.10.002","article-title":"ACC\/AHA\/SCAI\/SIR\/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine.","volume":"73","author":"Bailey","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250409","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","article-title":"Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.","volume":"4","author":"Dake","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"R4-20250409","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jvs.2019.01.080","article-title":"Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.","volume":"70","author":"Caradu","year":"2019","journal-title":"J Vasc Surg"},{"key":"R5-20250409","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00270-019-02332-4","article-title":"Comparative efficacy and safety of endovascular treatment modalities for femoropopliteal artery lesions: a network meta-analysis of randomized controlled trials.","volume":"43","author":"Zhou","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R6-20250409","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcin.2019.12.028","article-title":"A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE trial.","volume":"13","author":"Gou\u00ebffic","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R8-20250409","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcin.2021.01.026","article-title":"2-Year outcomes of the Eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions.","volume":"14","author":"Stavroulakis","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R9-20250409","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","article-title":"Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent.","volume":"44","author":"M\u00fcller-H\u00fclsbeck","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R10-20250409","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcin.2022.01.019","article-title":"1-Year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration.","volume":"15","author":"Iida","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"R12-20250409","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.","volume":"392","author":"Gray","year":"2018","journal-title":"Lancet"},{"key":"R13-20250409","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/1526602816650206","article-title":"Twelve month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease.","volume":"23","author":"M\u00fcller-H\u00fclsbeck","year":"2016","journal-title":"J Endovasc Ther"},{"key":"R14-20250409","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1526602820901723","article-title":"Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL Long Lesion Substudy of the Eluvia drug-eluting stent.","volume":"27","author":"Golzar","year":"2020","journal-title":"J Endovasc Ther"},{"key":"R15-20250409","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4244\/EIJV12I6A128","article-title":"Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model.","volume":"12","author":"Hou","year":"2016","journal-title":"EuroIntervention"},{"key":"R16-20250409","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jvir.2010.12.027","article-title":"Polymer-free paclitaxel-coated Zilver PTX stents: evaluation of pharmacokinetics and comparative safety in porcine arteries.","volume":"22","author":"Dake","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"R17-20250409","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ccd.23064","article-title":"Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses.","volume":"78","author":"Iida","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"R18-20250409","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease.","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250409","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jvs.2020.07.093","article-title":"Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.","volume":"73","author":"Schneider","year":"2021","journal-title":"J Vasc Surg"},{"key":"R20-20250409","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/15266028211023505","article-title":"Mortality rates after paclitaxel-coated device use in patients with occlusive femoropopliteal disease: an updated systematic review and meta-analysis of randomized controlled trials.","volume":"28","author":"Dinh","year":"2021","journal-title":"J Endovasc Ther"},{"key":"R21-20250409","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1526602820941800","article-title":"Fragility of the signal.","volume":"27","author":"Gou\u00ebffic","year":"2020","journal-title":"J Endovasc Ther"},{"key":"R22-20250409","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejvs.2019.12.034","article-title":"Long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis.","volume":"59","author":"Behrendt","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R23-20250409","doi-asserted-by":"crossref","first-page":"e008528","DOI":"10.1161\/CIRCINTERVENTIONS.119.008528","article-title":"Mortality after paclitaxel coated balloon angioplasty and stenting of superficial femoral and popliteal artery in the Vascular Quality Initiative.","volume":"13","author":"Bertges","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"R24-20250409","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/eurheartj\/ehz698","article-title":"Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.","volume":"41","author":"Freisinger","year":"2020","journal-title":"Eur Heart J"},{"key":"R25-20250409","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2214\/ajr.169.3.9275890","article-title":"MR imaging signal-intensity abnormalities after placement of arterial endoprostheses.","volume":"169","author":"Muller-Hulsbeck","year":"1997","journal-title":"AJR Am J Roentgenol"},{"key":"R26-20250409","doi-asserted-by":"crossref","first-page":"2050313X211014519","DOI":"10.1177\/2050313X211014519","article-title":"\u201cLow echoic area\u201d around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease.","volume":"9","author":"Soga","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"R27-20250409","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jvir.2014.03.026","article-title":"Nickel allergy in a patient with a nitinol stent in the superficial femoral artery.","volume":"25","author":"D\u2019Arrigo","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"R28-20250409","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jvs.2006.02.054","article-title":"Clinical presentation and vascular imaging in giant cell arteritis of the femoropopliteal and tibioperoneal arteries: analysis of four cases.","volume":"44","author":"Tato","year":"2006","journal-title":"J Vasc Surg"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1161\/CIRCULATIONAHA.122.059606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:25:21Z","timestamp":1744212321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1161\/CIRCULATIONAHA.122.059606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1161\/circulationaha.122.059606","relation":{},"ISSN":["0009-7322"],"issn-type":[{"value":"0009-7322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}